But because we don’t know what’s driving it, we don’t know what to go after.” The study was supported by Sanofi. Cree is a co ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

Sanofi is end­ing a Phase 2 clin­i­cal tri­al that’s test­ing a drug from De­nali for mul­ti­ple scle­ro­sis, putting a stop to the de­vel­op­ment plan. … ...

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi will keep a significant stake in the ... Finally, we've shared several positive Phase 3 readouts, including tolebrutinib, one of our BTK inhibitors, which is notable for its effect on ...

Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward-looking statements.

Sanofi SAN1.67%increase; green up pointing triangle reported third-quarter earnings and sales that beat analysts’ expectations, boosted by earlier-than-anticipated deliveries of flu and ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand ...